SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-000490 to TREVENA INC (TRVN) (CIK 0001429560)

TREVENA INC (TRVN) (CIK 0001429560)
Date: Jan. 16, 2024 · CIK: 0001429560 · Accession: 0000000000-24-000490

AI Filing Summary & Sentiment

File numbers found in text: 333-276458

Date
January 16, 2024
Author
Not clearly detected
Form
UPLOAD
Company
TREVENA INC (TRVN) (CIK 0001429560)

Letter

United States securities and exchange commission logo January 16, 2024 Barry Shin Chief Financial Officer Trevena, Inc. 955 Chesterbrook Boulevard, Suite 110 Chesterbrook, PA 19087 Re:Trevena, Inc. Registration Statement on Form S-3 Filed January 10, 2024 File No. 333-276458 Dear Barry Shin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott R. Jones, Esq.

Show Raw Text
United States securities and exchange commission logo
January 16, 2024
Barry Shin
Chief Financial Officer
Trevena, Inc.
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
Re:Trevena, Inc.
Registration Statement on Form S-3
Filed January 10, 2024
File No. 333-276458
Dear Barry Shin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Scott R. Jones, Esq.